Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061039 | 0.92 | HDAC1 (1.00) | HDAC1AURKB | |
| SCHEMBL6131202 | 0.87 | HDAC1 (0.84) | HDAC1AURKB | |
| SCHEMBL8350666 | 0.86 | AURKB (0.78) | HDAC1AURKB | |
| SCHEMBL6131078 | 0.85 | AURKB (0.79) | HDAC1AURKB | |
| SCHEMBL6919054 | 0.85 | AURKB (0.77) | HDAC1AURKB | |
| Lithium Ion SCHEMBL6919059 | 0.84 | AURKB (0.74) | HDAC1AURKB | |
| SCHEMBL1065095 | 0.84 | AURKB (0.79) | HDAC1AURKB | |
| SCHEMBL213867 | 0.84 | HDAC1 (0.86) | HDAC1AURKB | |
| SCHEMBL209760 | 0.84 | HDAC1 (0.85) | HDAC1AURKB | |
| SCHEMBL209892 | 0.81 | HDAC1 (0.68) | HDAC1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885AURKB 296/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885AURKB 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.